CCAAT/Enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia - Wikidata - wikimedia - TriplyDB

CCAAT/Enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia

CCAAT/Enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia

http://www.wikidata.org/entity/Q28209517

about

sameAs

Repression of transcriptional activity of C/EBPalpha by E2F-dimerization partner complexes N-terminal region of CCAAT/enhancer-binding protein epsilon is critical for cell cycle arrest, apoptosis, and functional maturation during myeloid differentiation Identification of a myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia.Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia CEBPA point mutations in hematological malignancies.Disruption of differentiation in human cancer: AML shows the way.Human α-defensin expression is not dependent on CCAAT/enhancer binding protein-ε in a murine model.Retinoid target genes in acute promyelocytic leukemia.ATOH1 Can Regulate the Tumorigenicity of Gastric Cancer Cells by Inducing the Differentiation of Cancer Stem Cells.Direct and indirect targeting of MYC to treat acute myeloid leukemia Transcription profiling of C/EBP targets identifies Per2 as a gene implicated in myeloid leukemia CCAAT/enhancer binding proteins alpha and epsilon cooperate with all-trans retinoic acid in therapy but differ in their antileukemic activities PML-retinoic acid receptor alpha inhibits PML IV enhancement of PU.1-induced C/EBPepsilon expression in myeloid differentiation.Animal models of acute myelogenous leukaemia - development, application and future perspectives.Deficiency of CCAAT/enhancer binding protein family DNA binding prevents malignant conversion of adenoma to carcinoma in NNK-induced lung carcinogenesis in the mouse The complex translocation (9;14;14) involving IGH and CEBPE genes suggests a new subgroup in B-lineage acute lymphoblastic leukemia.p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia.Transcriptional dysregulation during myeloid transformation in AML.Dysregulation of the C/EBPalpha differentiation pathway in human cancer.Runx1 deficiency permits granulocyte lineage commitment but impairs subsequent maturation.Combined staurosporine and retinoic acid induces differentiation in retinoic acid resistant acute promyelocytic leukemia cell lines.C/EBPα deregulation as a paradigm for leukemogenesis.C/EBPalpha and C/EBPvarepsilon induce the monocytic differentiation of myelomonocytic cells with the MLL-chimeric fusion gene.Increased CCAAT enhancer-binding protein epsilon (C/EBPepsilon) expression and premature apoptosis in myeloid cells expressing Gfi-1 N382S mutant associated with severe congenital neutropenia.ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression.Desferrioxamine induces leukemic cell differentiation potentially by hypoxia-inducible factor-1 alpha that augments transcriptional activity of CCAAT/enhancer-binding protein-alpha.Analysis of the interplay between all-trans retinoic acid and histone deacetylase inhibitors in leukemic cells.Evidence of functional interaction between NuMA-RARalpha and RXRalpha in an in vivo model of acute promyelocytic leukemia.CEBPA methylation as a prognostic biomarker in patients with de novo acute myeloid leukemia.DNA microarray expression profiling of a new t(8;13) AML case allows identification of possible leukemogenic transformation markers.Green tea polyphenol EGCG causes anti-cancerous epigenetic modulations in acute promyelocytic leukemia cells.Correlation of C/EBPα expression with response and resistance to imatinib in chronic myeloid leukaemia.

P2860

Q24300598-60E94699-9D4C-4165-A7CE-9E5AB6ABC775 Q28301469-20565BAB-E5CF-4EF9-AEE1-E1EE9A019943 Q33560404-FC782F6E-31BF-414A-BF72-58CFEFAD90D8 Q34340593-3D9DC765-64FB-4BE1-815B-852F088461F5 Q34388725-6BEEE627-874F-49C2-B8D1-2098C5BB9288 Q35058575-E874B73E-7A2F-4280-AC46-32D30F57A988 Q35127893-09B0077C-1201-404E-8453-C64F9A1C86C0 Q35217391-F4FDECAD-1EED-47FB-86CA-9A0AEDF58D72 Q35581773-5B0E942B-3E25-4D02-9F92-3E726368AFCC Q35798798-F5F5539B-4830-48E2-A2B4-02345D5C2F32 Q35848337-0C17A5F3-BBCB-4437-9903-5C49D79CD221 Q35849139-C4798CAD-A618-42F9-97CF-5B86B90A5FC1 Q35950186-D03CCB74-9FC9-45D7-A121-55B010811AEC Q36066980-02659B6C-C220-48EF-BB2F-F0A92CF99CF2 Q36544436-0613574B-C879-4419-80BB-A7FD7D679246 Q36727704-40F4BEEB-8638-4501-81D0-F3E96F4393E1 Q36848202-B142912D-6F3C-4936-8DD7-446040E5AC0D Q36890276-BB718844-4121-4E68-891F-7A529A5B71FA Q36970214-1FAD6F71-E92C-45AB-BBD9-411D29CDD20F Q37104787-7BE18CEE-7C11-4122-9D8D-40E924489925 Q37361836-B8DC546F-9CA6-4B92-8D8D-84553125834F Q37725693-56E6790C-78AA-4A92-9112-9B21B0BB8FDD Q39442731-88EC5506-1ABB-41D4-B127-10107A08A878 Q39942216-0815356A-2868-4FA2-BED1-2DACAB65EBB9 Q40311738-23B6BDE5-E452-41A5-A13E-182A5E689102 Q40340238-E1CB1279-DBB0-4040-BC80-070191A27B26 Q40420598-ECE8039D-06D4-4BA0-8E1F-9464EE2B0592 Q40468248-50901B16-BC26-4C87-94ED-D3042DED7436 Q42814510-BC729EE7-0E20-4501-A66B-007846829DEF Q43466307-D87CBB53-8418-4760-8C76-21B32A3EF3AE Q47137215-D37A0120-D983-4707-9E27-699A8A301691 Q50198239-2135D7F2-297B-484E-A565-B766F0BA9601 Q54275092-7061FE81-0AF1-4F9B-877F-B70E3F4C8768

P2860

CCAAT/Enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia

http://www.wikidata.org/entity/Q28209517

description

2003 nî lūn-bûn

@nan

2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

CCAAT/Enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia

@ast

CCAAT/Enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia

@en

CCAAT/Enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia

@nl

type

label

CCAAT/Enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia

@ast

CCAAT/Enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia

@en

CCAAT/Enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia

@nl

prefLabel

CCAAT/Enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia

@ast

CCAAT/Enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia

@en

CCAAT/Enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia

@nl

P1433

Q28209517-C8B8477C-A321-48FB-BAEB-EC2B592C3F5D

P1476

Q28209517-04316FF5-38B1-45A2-BC55-5579BD7465E3

P2093

Q28209517-0053BAB4-4DF4-4174-A219-30A832E4B2BA

Q28209517-318BE608-0AFA-41CC-9CB4-E9495DAFFB2B

Q28209517-3823B9D2-71A2-4D5A-B7D6-CD7A1836AED2

Q28209517-5DA08388-3D3A-4377-8C26-10FA171E2D6C

Q28209517-69B0B102-6223-43C5-B82A-7BA89A7DE918

Q28209517-8BC8338B-4114-4EAC-973E-D8F64FECCA24

Q28209517-95D81789-FEF9-4107-A4E2-336E0A6EB50F

Q28209517-A55254C1-76B9-4B88-9718-CD580D8348C0

Q28209517-BB578B13-2FF8-4211-880E-6EBCBFFC9C3D

Q28209517-EA8EFED8-94FC-4F35-B657-C2070945C647

P304

Q28209517-0BE3ADB3-85C3-4BBF-A97B-483266420410

P31

Q28209517-9902F614-D30C-4910-B058-9423222C54AB

P356

Q28209517-5003A1EE-DE6B-4A4A-BB5C-2FA08AF6BB09

P407

Q28209517-0922019E-533F-4339-8D90-A0FDCC165636

P433

Q28209517-BBBD6DF1-75DF-48FF-8286-C1C730453523

P478

Q28209517-510ECDA5-9C80-41C4-827F-C80FA719511B

P577

Q28209517-E68A09C0-DAC4-46A9-9634-29E5846FB6D0

P5875

Q28209517-021B54D8-FA77-4D3D-8841-1CEFF4BAFFE8

P698

Q28209517-59C0AE06-6B07-49D4-B2B0-813A1336E1BD

P921

Q28209517-5B7B4D22-B5E6-487A-B8CB-A3AFF685EBD9

P356

BLOOD-2002-05-1374

P1433

P1476

CCAAT/Enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia

@en

P2093

Bao-Tran H Truong

http://www.w3.org/2001/XMLSchema#string

Daniel G Tenen

http://www.w3.org/2001/XMLSchema#string

Danilo Perrotti

http://www.w3.org/2001/XMLSchema#string

Dorothy J Park

http://www.w3.org/2001/XMLSchema#string

H Phillip Koeffler

http://www.w3.org/2001/XMLSchema#string

Hideaki Nakajima

http://www.w3.org/2001/XMLSchema#string

Naohide Watanabe

http://www.w3.org/2001/XMLSchema#string

Scott C Kogan

http://www.w3.org/2001/XMLSchema#string

Tracey A Lodie

http://www.w3.org/2001/XMLSchema#string

Young-Jin Lee

http://www.w3.org/2001/XMLSchema#string

P304

1141-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2002-05-1374

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P577

2003-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5326669

http://www.w3.org/2001/XMLSchema#string

P698

12393450

http://www.w3.org/2001/XMLSchema#string

P921